Open Access

MCP‑1 targeting: Shutting off an engine for tumor development (Review)

  • Authors:
    • Liang Wang
    • Jinxin Lan
    • Jiaping Tang
    • Na Luo
  • View Affiliations

  • Published online on: November 19, 2021     https://doi.org/10.3892/ol.2021.13144
  • Article Number: 26
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A large amount of research has proven that monocyte chemotactic protein‑1 (MCP‑1) is associated with different types of disease, including autoimmune, metabolic and cardiovascular diseases. In addition, several studies have found that MCP‑1 is associated with tumor development. MCP‑1 expression level in the tumor microenvironment is associated with tumor development, including in tumor invasion and metastasis, angiogenesis, and immune cell infiltration. However, the precise mechanism involved is currently being investigated. MCP‑1 exerts its effects mainly via the MCP‑1/C‑C motif chemokine receptor 2 axis and leads to the activation of classical signaling pathways, such as PI3K/Akt/mTOR, ERK/GSK‑3β/Snail, c‑Raf/MEK/ERK and MAPK in different cells. The specific mechanism is still under debate; however, target therapy utilizing MCP‑1 as a neutralizing antibody has been found to have a detrimental effect on tumor development. The aim of the present review was to examine the effect of MCP‑1 on tumor development from several aspects, including its structure, its involvement in signaling pathways, the participating cells, and the therapeutic agents targeting MCP‑1. The improved understanding into the structure of MCP‑1 and the mechanism of action may facilitate new and practical therapeutic agents to achieve maximum performance in the treatment of patients with cancer.
View Figures
View References

Related Articles

Journal Cover

January-2022
Volume 23 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang L, Lan J, Tang J and Luo N: MCP‑1 targeting: Shutting off an engine for tumor development (Review). Oncol Lett 23: 26, 2022.
APA
Wang, L., Lan, J., Tang, J., & Luo, N. (2022). MCP‑1 targeting: Shutting off an engine for tumor development (Review). Oncology Letters, 23, 26. https://doi.org/10.3892/ol.2021.13144
MLA
Wang, L., Lan, J., Tang, J., Luo, N."MCP‑1 targeting: Shutting off an engine for tumor development (Review)". Oncology Letters 23.1 (2022): 26.
Chicago
Wang, L., Lan, J., Tang, J., Luo, N."MCP‑1 targeting: Shutting off an engine for tumor development (Review)". Oncology Letters 23, no. 1 (2022): 26. https://doi.org/10.3892/ol.2021.13144